ARQT News and Press, Arcutis Biotherapeutics Inc.

WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Christopher “Chris” Peetz has been ...

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its second quarter 2026 financial...

SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the a...

2026-07-08 10:56:25 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound Arcutis Biotherape...

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label pharmacokinetic (PK) study 1 million children under the age of 2 are treated topically fo...

2026-07-03 08:57:20 ET Choosing between Arcutis Biotherapeutics (NASDAQ:ARQT) and Vertex Pharmaceuticals (NASDAQ:VRTX) involves weighing a high-growth newcomer against a cash-generating giant. Both companies aim to dominate their respective niches within the healthcare secto...

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis Connects eligible individuals with independent, board-certified dermatologists through a streamlined digital experience for...

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration of use Seventh FDA approval for ZORYVE i...

2026-06-23 19:35:13 ET Sue-Jean Lin, a director of Arcutis Biotherapeutics (NASDAQ:ARQT) , reported the sale of 4,946 shares of common stock on June 15, 2026, as disclosed in this SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($24.38); post-trans...

2026-06-09 17:22:10 ET Arcutis Biotherapeutics, Inc. (ARQT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 2:00 PM EDT... Read the full article on Seeking Alpha For further details see: Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs ...